504 related articles for article (PubMed ID: 10519392)
1. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
2. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days.
Schild LJ; Divi RL; Beland FA; Churchwell MI; Doerge DR; Gamboa da Costa G; Marques MM; Poirier MC
Cancer Res; 2003 Sep; 63(18):5999-6003. PubMed ID: 14522927
[TBL] [Abstract][Full Text] [Related]
3. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.
Shibutani S; Suzuki N; Laxmi YR; Schild LJ; Divi RL; Grollman AP; Poirier MC
Cancer Res; 2003 Aug; 63(15):4402-6. PubMed ID: 12907611
[TBL] [Abstract][Full Text] [Related]
4. Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods.
Schild LJ; Phillips DH; Osborne MR; Hewer A; Beland FA; Churchwell MI; Brown K; Gaskell M; Wright E; Poirier MC
Mutagenesis; 2005 Mar; 20(2):115-24. PubMed ID: 15755801
[TBL] [Abstract][Full Text] [Related]
5. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry.
Gamboa da Costa G; Marques MM; Beland FA; Freeman JP; Churchwell MI; Doerge DR
Chem Res Toxicol; 2003 Mar; 16(3):357-66. PubMed ID: 12641436
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization, and quantitation of a 4-aminobiphenyl-DNA adduct standard.
Beland FA; Doerge DR; Churchwell MI; Poirier MC; Schoket B; Marques MM
Chem Res Toxicol; 1999 Jan; 12(1):68-77. PubMed ID: 9894020
[TBL] [Abstract][Full Text] [Related]
7. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
8. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
Li D; Dragan Y; Jordan VC; Wang M; Pitot HC
Cancer Res; 1997 Apr; 57(8):1438-41. PubMed ID: 9108442
[TBL] [Abstract][Full Text] [Related]
9. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
[TBL] [Abstract][Full Text] [Related]
10. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
11. Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice.
Umemoto A; Komaki K; Monden Y; Suwa M; Kanno Y; Kitagawa M; Suzuki M; Lin CX; Ueyama Y; Momen MA; Ravindernath A; Shibutani S
Chem Res Toxicol; 2001 Aug; 14(8):1006-13. PubMed ID: 11511174
[TBL] [Abstract][Full Text] [Related]
12. Inefficient repair of tamoxifen-DNA adducts in rats and mice.
Kim SY; Suzuki N; Laxmi YR; Shibutani S
Drug Metab Dispos; 2006 Feb; 34(2):311-7. PubMed ID: 16299164
[TBL] [Abstract][Full Text] [Related]
13. Development of a 32P-postlabeling method for the detection of 1, N2-propanodeoxyguanosine adducts of 2-hexenal in vivo.
Schuler D; Budiawan B; Eder E
Chem Res Toxicol; 1999 Apr; 12(4):335-40. PubMed ID: 10207122
[TBL] [Abstract][Full Text] [Related]
14. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans.
Beland FA; Churchwell MI; Doerge DR; Parkin DR; Malejka-Giganti D; Hewer A; Phillips DH; Carmichael PL; Gamboa da Costa G; Marques MM
J Natl Cancer Inst; 2004 Jul; 96(14):1099-104. PubMed ID: 15265972
[TBL] [Abstract][Full Text] [Related]
15. DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene.
Gamboa da Costa G; Pereira PC; Churchwell MI; Beland FA; Marques MM
Chem Res Toxicol; 2007 Feb; 20(2):300-10. PubMed ID: 17261033
[TBL] [Abstract][Full Text] [Related]
16. Identification of hepatic tamoxifen-DNA adducts in mice: alpha-(N(2)-deoxyguanosinyl)tamoxifen and alpha-(N(2)-deoxyguanosinyl)tamoxifen N-oxide.
Umemoto A; Monden Y; Suwa M; Kanno Y; Suzuki M; Lin CX; Ueyama Y; Momen MA; Ravindernath A; Shibutani S; Komaki K
Carcinogenesis; 2000 Sep; 21(9):1737-44. PubMed ID: 10964106
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen.
Divi RL; Dragan YP; Pitot HC; Poirier MC
Carcinogenesis; 2001 Oct; 22(10):1693-9. PubMed ID: 11577011
[TBL] [Abstract][Full Text] [Related]
18. Mutagenic potential of alpha-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen.
Terashima I; Suzuki N; Shibutani S
Cancer Res; 1999 May; 59(9):2091-5. PubMed ID: 10232593
[TBL] [Abstract][Full Text] [Related]
19. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.
Phillips DH; Hewer A; Osborne MR; Cole KJ; Churchill C; Arlt VM
Mutagenesis; 2005 Jul; 20(4):297-303. PubMed ID: 15928012
[TBL] [Abstract][Full Text] [Related]
20. Highly sensitive chemiluminescence immunoassay for benzo[a]pyrene-DNA adducts: validation by comparison with other methods, and use in human biomonitoring.
Divi RL; Beland FA; Fu PP; Von Tungeln LS; Schoket B; Camara JE; Ghei M; Rothman N; Sinha R; Poirier MC
Carcinogenesis; 2002 Dec; 23(12):2043-9. PubMed ID: 12507927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
